NCT00239980View on ClinicalTrials.gov

Fragmin in Ovarian Cancer: Utility on Survival (FOCUS)

PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Ovarian Cancer
Interventions
DRUG

dalteparin

50, 100, 150 IU/kg administered subcutaneously once daily for 3 cycles of chemotherapy

Trial Locations (9)

T6G 1Z2

Cross Cancer Institute, Edmonton

V3V 1Z2

B.C. Cancer Agency- Fraser Valley Centre, Surrey

V5Z 4E6

B.C. Cancer Agency- Vancouver Centre, Vancouver

B3H 1V7

Nova Scotia Cancer Centre, Halifax

L8V 5C2

Juravinski Cancer Centre, Hamilton

N6A 4G5

London Health Sciences Centre, London

K1H 8L6

The Ottawa Hospital Cancer Centre, Ottawa

M5G 2M9

Princess Margaret Hospital, Toronto

H2L 4M1

Hopital Notre-Dame, Montreal

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Ontario Clinical Oncology Group (OCOG)

OTHER

NCT00239980 - Fragmin in Ovarian Cancer: Utility on Survival (FOCUS) | Biotech Hunter | Biotech Hunter